I'll be happy if we treat 30 before the EOFY - at least that will see us in profit for the 2025 financial year... hehe
200 patients a year including off label would be a wonderful initial effort IMO
EU Takeda partnership is next for GVHD, IBD, Crohns etc is my bet
Perhaps the blackout period for Directors will be lifted today given financials and the long awaited Ryoncil pricing have been released ? Either way I think shorts might have a bad day ... oh well
GLTAH
MSB Price at posting:
$2.46 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)